Phio Pharmaceuticals Corp.

PHIO Healthcare Biotechnology

In the quarter to June 2026, EPS grew 20.0% and free cash flow fell 58.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.87 0.06 −6.45%
Market cap
$10.8M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
1/9
Altman Z
−18.25
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
6.90 16.03 18.32 8.39
Net Debt/EBITDA
4.27 8.30 4.09 3.05
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.38) (0.35) (0.34) (0.35)
Book value per Share
1.80 3.37 1.42 1.08
Free Cash Flow
(2.09) (2.08) (4.00) (4.03)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates